MX2021006464A - Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo. - Google Patents

Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo.

Info

Publication number
MX2021006464A
MX2021006464A MX2021006464A MX2021006464A MX2021006464A MX 2021006464 A MX2021006464 A MX 2021006464A MX 2021006464 A MX2021006464 A MX 2021006464A MX 2021006464 A MX2021006464 A MX 2021006464A MX 2021006464 A MX2021006464 A MX 2021006464A
Authority
MX
Mexico
Prior art keywords
meisoindigo
polymorphic form
inflammatory
modified formulation
methylisoindigo
Prior art date
Application number
MX2021006464A
Other languages
English (en)
Inventor
Longgui Wang
Original Assignee
Natrogen Therapeutics Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natrogen Therapeutics Int Inc filed Critical Natrogen Therapeutics Int Inc
Publication of MX2021006464A publication Critical patent/MX2021006464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0025—Crystal modifications; Special X-ray patterns
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
    • C09B67/0096—Purification; Precipitation; Filtration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se relaciona a una forma de cristal novedosa, procedimientos de manufactura, composiciones farmacéuticas, formulaciones y medicamentos que comprenden un N-metilisoindigo cristalino, métodos de preparación y el uso de N-metilisoindigo cristalino para preparar un medicamento para prevenir cáncer o tratar cáncer o una enfermedad inflamatoria relacionada asociada con la expresion de citocina proinflamatoria y/o expresion reducida de citocinas anti inflamatorias.
MX2021006464A 2018-12-07 2019-11-21 Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo. MX2021006464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776965P 2018-12-07 2018-12-07
PCT/US2019/062704 WO2020117487A1 (en) 2018-12-07 2019-11-21 Polymorphic form of meisoindigo and modified formulation of meisoindigo

Publications (1)

Publication Number Publication Date
MX2021006464A true MX2021006464A (es) 2021-09-28

Family

ID=70974812

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006464A MX2021006464A (es) 2018-12-07 2019-11-21 Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo.

Country Status (9)

Country Link
US (1) US20220009889A1 (es)
EP (1) EP3891141A4 (es)
JP (1) JP2022511554A (es)
KR (1) KR20210102335A (es)
CN (1) CN113365990A (es)
CA (1) CA3121726A1 (es)
IL (1) IL283703A (es)
MX (1) MX2021006464A (es)
WO (1) WO2020117487A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327658A1 (en) 2021-04-21 2024-02-28 Sumitomo Chemical Company Limited Method for controlling disease-transmitting insects using condensed heterocyclic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
CA2469649C (en) * 2001-12-13 2011-05-03 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
WO2013142817A2 (en) * 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
PT106237B (pt) * 2012-03-30 2015-03-19 Hovione Farmaci Ncia S A Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas
CN106176720A (zh) * 2016-08-17 2016-12-07 武汉大学 甲异靛在制备抗炎药物中的应用

Also Published As

Publication number Publication date
CA3121726A1 (en) 2020-06-11
KR20210102335A (ko) 2021-08-19
EP3891141A1 (en) 2021-10-13
CN113365990A (zh) 2021-09-07
JP2022511554A (ja) 2022-01-31
US20220009889A1 (en) 2022-01-13
IL283703A (en) 2021-07-29
WO2020117487A1 (en) 2020-06-11
EP3891141A4 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
PH12020550341A1 (en) Niraparib formulations
AU2016354007A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CO2022008606A2 (es) Derivados de piridopirimidinona como antagonistas de ahr
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
MX2021006464A (es) Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo.
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CL2020001791A1 (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
WO2015166418A3 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
MX2021007032A (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos.
PH12020500120A1 (en) Pharmaceutical compositions
MX2021007150A (es) Compuesto farmaceutico, metodo de fabricacion y uso como agente medicinal.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
WO2018067638A3 (en) High mobility group b1 protein inhibitors